Marc Goodman
Stock Analyst at Leerink Partners
(3.65)
# 738
Out of 5,182 analysts
99
Total ratings
57.14%
Success rate
25.23%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANE Veradermics | Maintains: Outperform | $75 → $90 | $76.05 | +18.35% | 2 | Apr 22, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $215 → $225 | $201.67 | +11.57% | 6 | Apr 22, 2026 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $40 → $35 | $20.48 | +70.90% | 2 | Apr 22, 2026 | |
| DFTX Definium Therapeutics | Maintains: Outperform | $23 → $30 | $23.09 | +29.93% | 1 | Apr 22, 2026 | |
| SGP SpyGlass Pharma | Initiates: Outperform | $42 | $24.30 | +72.84% | 1 | Mar 3, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $183.88 | +11.49% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $2.42 | +230.58% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $31.76 | -5.54% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $2.85 | +75.44% | 1 | Nov 17, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $32.19 | +5.62% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $50 | $10.72 | +366.42% | 7 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $10 | $17.64 | -43.31% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $10 → $1 | $7.32 | -86.34% | 3 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $10.30 | +210.68% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $172.00 | -85.47% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $4.91 | +307.33% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $131.01 | -12.22% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $191.52 | +61.86% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $57.01 | -19.31% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $22.00 | -4.55% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.96 | +237.84% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $33.50 | -19.40% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $1.68 | +795.52% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $561.17 | -51.89% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $204.01 | -52.94% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $59.38 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $112.55 | -40.47% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $11.82 | +729.10% | 7 | Oct 5, 2017 |
Veradermics
Apr 22, 2026
Maintains: Outperform
Price Target: $75 → $90
Current: $76.05
Upside: +18.35%
Jazz Pharmaceuticals
Apr 22, 2026
Maintains: Outperform
Price Target: $215 → $225
Current: $201.67
Upside: +11.57%
Denali Therapeutics
Apr 22, 2026
Maintains: Outperform
Price Target: $40 → $35
Current: $20.48
Upside: +70.90%
Definium Therapeutics
Apr 22, 2026
Maintains: Outperform
Price Target: $23 → $30
Current: $23.09
Upside: +29.93%
SpyGlass Pharma
Mar 3, 2026
Initiates: Outperform
Price Target: $42
Current: $24.30
Upside: +72.84%
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $183.88
Upside: +11.49%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $2.42
Upside: +230.58%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $31.76
Upside: -5.54%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $2.85
Upside: +75.44%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $32.19
Upside: +5.62%
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $10.72
Upside: +366.42%
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $17.64
Upside: -43.31%
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $7.32
Upside: -86.34%
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $10.30
Upside: +210.68%
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $172.00
Upside: -85.47%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $4.91
Upside: +307.33%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $131.01
Upside: -12.22%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $191.52
Upside: +61.86%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $57.01
Upside: -19.31%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $22.00
Upside: -4.55%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.96
Upside: +237.84%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $33.50
Upside: -19.40%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $1.68
Upside: +795.52%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $561.17
Upside: -51.89%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $204.01
Upside: -52.94%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $59.38
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $112.55
Upside: -40.47%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $11.82
Upside: +729.10%